APD 12 Powder for Infants
Providing 10 hardy strains of probiotics with a strong potency of 10 bullion CFUs. This highly potent formula for infants from birth until age 3 supplies 5 strains of Lactobacillus probiotics and 5 strains of Bifidobacterium. These strains have shown their ability to address relief of atopic eczema,support the immune system and reduce many allergies in infants, plus many other benefits.
Also reduces many allergies in infants. Clinical studies have shown colic and thrush relief through the consumption of many of the probiotic strains in our infant formula.
Free of milk/casein, eggs, fish, shellfish, tree nuts, peanuts, wheat/gluten, corn, yeast, and soybeans. Contains no artificial colors, flavors, preservatives, artificial additives and Non-GMO.
ProDermix Kosher APD-12 Probiotic Supplement 10 Billion Plus CFUs Powder for Infants Suggested Use:
Take 1/4 teaspoon daily or as directed by a healthcare professional.
L. casei helps create an intestinal environment favorable to the growth of other probiotic organisms while antagonizing pathogens such as E. coli and Staphylococcus aureus. Studies indicate L. casei helps improve conditions of constipation in infants and children. It has also shown to suppress allergic responses in preschool children. A double‐blind, controlled clinical trial involving 231 preterm infants found supplementing of L. casei along with B. breve for the first month of life significantly reduces the risk of developing severe enterocolitis.
L. gasseri exhibits good mucosal adherence, bile‐tolerance, and is one of the few known bacteria capable of enzymatically binding and sustaining fructose into the beneficial prebiotic, inulin. L. gasseri produces a number of antimicrobial substances including hydrogen peroxide. L. gasseri produces gassericin which is a killer bacteria that kills E. coli and other harmful bacteria (reported in Nature Reviews Microbiology). A double‐blind, placebo‐controlled clinical study found supplementation with a probiotic blend containing L. gasseri, B. longum, and B. bifidum significantly reduced the duration and symptom severity of common cold infections.
L. paracasei is an acid‐tolerant organism that survives passage through the intestinal tract and promotes the growth of other lactobacilli. L. paracasei is antagonistic to Candida albicans among other pathogens. Clinical studies have documented supportive benefits of L. paracasei in conditions ranging from non‐rotaviral diarrhea to allergic disorders. A prospective study examining fecal specimens of over 500 infants found colonization of the intestinal tract with L. paracasei significantly reduces the risk of developing atopic dermatitis.
This Lactobacillus is perhaps the most clinically studied of all probiotic organisms. L rhamnosus has very good adherence characteristics to the mucosal lining and exhibits extraordinary defiance towards microbial pathogens. The following pathogens were studied as being antagonized successfully by L. rhamnosus: E. coli, C. difficile C. albicans, Klebsiella pneumonia, S. aureus and Shigella among others. In clinical trials, L. rhamnosus has proven highly effective at reducing the risk and severity of infant diarrhea. Trials have also demonstrated that L. rhamnosus administered prenatally to expectant mothers and postnatal to their infants significantly lowers the risk of developing eczema during childhood.
L. salivarius is a resident of the intestinal tract with good survival and adherence characteristics. Preclinical research indicates L. salivarius favorably modulates inflammatory and allergic reactions. Studies involving mice with allergy induced asthma, showed L. salivarius significantly lessened the airway obstructiveness. In studies involving mice with allergy induced asthma, L. salivarius significantly
lessened the obstructiveness of the airway passages.
B. bifidum produces enzymes that help degrade dietary proteins and digestion‐resistant carbohydrates such as lactose. It has a normalizing effect on colonic performance and has been shown to rapidly
reduce stool frequency in infants with both rotaviral and non‐rotaviral diarrhea. Studies suggest B. bifidum has important immunoregulatory effects. A controlled clinical trial involving expectant mothers with a family history of allergic disorders found administration of a formula containing B. bifidum, B. lactis, and Lactobacillus acidophilus significantly reduced the incidence of eczema in their infant offspring during the first 12 months of life. A trial in which B. bifidum, B. lactis, and Lactococcus lactis was administered both prenatally to mothers and postnatally to their offspring demonstrated a preventive effect of eczema at ages one and two.
B. breve is the predominant species of Bifidobacteruim found in fecal samples of breastfed infants. Compared to other bifidobacteria, B. breve exhibits superior survival capacity in the presence of antibiotics. It also produces substantial quantities of lactase and may help mitigate symptoms of lactose intolerance. Studies also indicate B. breve may be useful as increasing antibody responses to influenza, polio, and possibly other viral organisms. A double‐blind, placebo‐controlled trial found administration of B. breve along with prebiotics significantly reduced wheezing and other respiratory symptoms in atopic infants at high risk of developing asthma.
As its name implies, B. infantis is naturally found in the intestinal tracts of infants. B. infantis is highly antagonistic to intestinal pathogens. It also has a strong suppressive effect on Bacteroides vulgatus, a bacteria thought to play an important role in the development of inflammatory bowel disease (IBD).
This hardy organism is acid‐resistant and displays and exceptionally high adhesive capacity to human intestinal mucus. Like L. paracasei, B. lactis secretes peptidase enzymes that help facilitate the digestion of dietary allergens like casein. Added to infant formulas, B. Lactis has been shown to reduce the incidence of diarrhea in residential can childcare settings and to improve weight gain in preterm, antibiotic‐treated infants. In a randomized, double‐blind study, administration of B. lactis to infants with atopic eczema for two months led to reduced levels of serum and significant improvements in skin condition. Trials utilizing B. lactis together with B. bifidum and other probiotic organisms have likewise reported significant reductions in the incidence of eczema among high‐risk infants.
B. longum is among the first colonizers of the newborn intestinal tract and, like B. breve and B. infantis, predominates in the microflora of healthy, breastfed infants. B. longum supplementation significantly reduces diarrhea and abdominal pain for persons taking antibiotics.
|Supports Intestinal Flora, Immune System, Thrush, Colic, Diarrhea, etc.|
|FREE of Common Allergens, Gluten, Dairy, Eggs, Nuts, etc.|
|60 Powder Servings (1 gram or 1/4 teaspoon) 10 Billion CFUs each|
Must be refrigerated and tightly closed to guarantee full potency until expiration date.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.